用palbociclib和exemestane治疗的患者的慢性髓性白血病:一个病例报告
Lishan Xu1, Lu Gan1, Shuai Song2
1Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
AME case reports
|May 7, 2025
概括
循环素依赖性激酶4/6 (CDK4/6) 抑制剂是HR+乳腺癌的标准. 一种罕见的慢性髓性白血病 (CML) 发生,需要调整治疗,但允许继续使用CDK4/6抑制剂治疗并进行监测.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 激素受体阳性 (HR+),人体表皮生长因子受体2-阴性 (HER2-) 乳腺癌是最常见的亚型.
- 结合内分泌疗法 (ET) 的循环素依赖性激酶4/6 (CDK4/6) 抑制剂是晚期HR+乳腺癌的标准.
- 虽然已知诸如中性质衰竭等血液学不良影响,但二次血液学恶性瘤很少见.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...